Literature DB >> 12209152

The druggable genome.

Andrew L Hopkins1, Colin R Groom.   

Abstract

An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.

Entities:  

Mesh:

Year:  2002        PMID: 12209152     DOI: 10.1038/nrd892

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  942 in total

1.  Insights into the Basal Activity and Activation Mechanism of the β1 Adrenergic Receptor Using Native Mass Spectrometry.

Authors:  Agni F M Gavriilidou; Hanna Hunziker; Daniel Mayer; Ziva Vuckovic; Dmitry B Veprintsev; Renato Zenobi
Journal:  J Am Soc Mass Spectrom       Date:  2018-12-03       Impact factor: 3.109

2.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

3.  Reprogramming chaperone pathways to improve membrane protein expression in Escherichia coli.

Authors:  Brent L Nannenga; François Baneyx
Journal:  Protein Sci       Date:  2011-07-07       Impact factor: 6.725

4.  In silico work flow for scaffold hopping in Leishmania.

Authors:  Barnali Waugh; Ambarnil Ghosh; Dhananjay Bhattacharyya; Nanda Ghoshal; Rahul Banerjee
Journal:  BMC Res Notes       Date:  2014-11-17

5.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

6.  Coordinating the impact of structural genomics on the human α-helical transmembrane proteome.

Authors:  Ursula Pieper; Avner Schlessinger; Edda Kloppmann; Geoffrey A Chang; James J Chou; Mark E Dumont; Brian G Fox; Petra Fromme; Wayne A Hendrickson; Michael G Malkowski; Douglas C Rees; David L Stokes; Michael H B Stowell; Michael C Wiener; Burkhard Rost; Robert M Stroud; Raymond C Stevens; Andrej Sali
Journal:  Nat Struct Mol Biol       Date:  2013-02       Impact factor: 15.369

Review 7.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

8.  Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors.

Authors:  Xun Shang; Fillipo Marchioni; Chris R Evelyn; Nisha Sipes; Xuan Zhou; William Seibel; Matthew Wortman; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Label-Free Quantification of Small-Molecule Binding to Membrane Proteins on Single Cells by Tracking Nanometer-Scale Cellular Membrane Deformation.

Authors:  Fenni Zhang; Wenwen Jing; Ashley Hunt; Hui Yu; Yunze Yang; Shaopeng Wang; Hong-Yuan Chen; Nongjian Tao
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

10.  Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion.

Authors:  Jean B Regard; Hiroshi Kataoka; David A Cano; Eric Camerer; Liya Yin; Yao-Wu Zheng; Thomas S Scanlan; Matthias Hebrok; Shaun R Coughlin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.